TechnoPhage, SA - From science to innovative biopharmaceuticals

Inflam.PT project

Project title | Inflam.PT
Project code | 011261
Main objective | Development of an innovative therapeutic agent for autoimmune diseases
Region of intervention | Lisbon
Beneficiary entity | TECHNOPHAGE, INVESTIGAÇÃO E DESENVOLVIMENTO EM BIOTECNOLOGIA S.A.
Approval date | 13 May 2016
Start date | January 2016
End date | December 2017
Total eligible cost | 431.539,09€
Regional public financial support | 172.637,24€
Objectives, activities and expected results | Inflam.PT project consists in the development of a specific antibody for the treatment of rheumatoid arthritis and systemic lupus erythematosus. Both diseases have a major incidence in the Asian region, particularly in China.
Inflam.PT project targets a proinflammatory cytokine that plays a role in T cell activation, acute phase protein production in response to inflammation, induction of immunoglobulin production, and stimulation of osteoclast differentiation and activation.




NeuroGoInter project

Project title | NeuroGoInter
Project code | 002452
Main objective | Internationalization of the area of R&D of neurology
Region of intervention | Lisbon
Beneficiary entity | TECHNOPHAGE, INVESTIGAÇÃO E DESENVOLVIMENTO EM BIOTECNOLOGIA S.A.
Approval date | 14 September 2015
Start date | December 2015
End date | November 2017
Total eligible cost | 99.275,00€
Regional public financial support | 44.673,75€
Objectives, activities and expected results | NeuroGoInter project intends to initiate the internationalization process of TA-111 and TZ-113 products in the markets of Alzheimer's disease and Parkinson's disease, respectively. Currently, TechnoPhage faces two challenges, chained in time:
- a first phase, under the NeuroGoInter project, broadening its international network and promoting advances in the R&D of TA-111 and TZ-1113 products with a view to establish partnerships with larger pharmaceutical companies for the clinical co-development of both products;
- in a second phase, planned for 2019, to find a buyer for both products, after the completion of the clinical phase IIa.

TechnoPhage intends to begin the process of internationalization of these two products in a global scale, focusing on the geographical areas in which these two neurological diseases are most prevalent and incident: USA, Europe, and Asia.